Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial

JACC: Heart Failure

Volumn 4, Issue 2, 2016, Pages 152-158

  Vardeny, Orly ^a   Claggett, Brian ^b   Udell, Jacob A ^c   Packer, Milton ^d   Zile, Michael ^e   Rouleau, Jean ^f   Swedberg, Karl ^g,h   Desai, Akshay S ^b   Lefkowitz, Martin ⁱ   Shi, Victor ⁱ   McMurray, John J V ^j   Solomon, Scott D ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f MONTREAL HEART INSTITUTE   (Canada)

^g UNIVERSITY OF GOTHENBURG   (Sweden)

^h NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

more..

Author keywords

Chronic heart failure; Clinical trial; Influenza vaccination

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; INFLUENZA VACCINE; MINERALOCORTICOID ANTAGONIST; SACUBITRIL PLUS VALSARTAN;

ADULT; AGE; ALL CAUSE MORTALITY; ARTICLE; ASIA; BELGIUM; CAUCASIAN; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HEART FAILURE; HEART RATE; HOSPITALIZATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NETHERLANDS; NEW YORK HEART ASSOCIATION CLASS; NORTH AMERICA; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; UNITED KINGDOM; AGED; CLINICAL TRIAL; COMPLICATION; DOUBLE BLIND PROCEDURE; EPIDEMIOLOGY; EUROPE; IMMUNOLOGY; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL RATE; TRENDS; UNITED STATES; VACCINATION;

AGED; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HEART FAILURE; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; UNITED STATES; VACCINATION;

EID: 84959141090     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2015.10.012     Document Type: Article

References (26)

1. Mertz D., Kim T.H., Johnstone J., et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ (Clin Res Ed) 2013, 347:f5061.
2. Smeeth L., Thomas S.L., Hall A.J., Hubbard R., Farrington P., Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004, 351:2611-2618.
3. Warren-Gash C., Smeeth L., Hayward A.C. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis 2009, 9:601-610.
4. Sandoval C., Walter S.D., Krueger P., et al. Risk of hospitalization during influenza season among a cohort of patients with congestive heart failure. Epidemiology and infection 2007, 135:574-582.
5. Grohskopf L.A., Olsen S.J., Sokolow L.Z., et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) - United States, 2014-15 influenza season. MMWR Morb Mortal Wkly Rep 2014, 63:691-697.
6. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013, 62:e147-e239.
7. Udell J.A., Zawi R., Bhatt D.L., et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA 2013, 310:1711-1720.
8. Lainscak M., Cleland J.G., Lenzen M.J., et al. Nonpharmacologic measures and drug compliance in patients with heart failure: data from the EuroHeart Failure Survey. Am J Cardiol 2007, 99:31-37D.
9. Corrales-Medina V.F., Alvarez K.N., Weissfeld L.A., et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA 2015, 313:264-274.
10. McMurray J.J., Packer M., Desai A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014, 371:993-1004.
11. McMurray J.J., Packer M., Desai A.S., et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2013, 15:1062-1073.
12. Davis M.M., Taubert K., Benin A.L., et al. Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology. J Am Coll Cardiol 2006, 48:1498-1502.
13. Heidenreich P.A., Zhao X., Hernandez A.F., et al. Impact of an expanded hospital recognition program for heart failure quality of care. J Am Heart Assoc 2014, 3:e000950.
14. Hebert K., Marzouka G., Arcement L., et al. Prevalence of vaccination rates in systolic heart failure: a prospective study of 549 patients by age, race, ethnicity, and sex in a heart failure disease management program. Congest Heart Fail 2010, 16:278-283.
15. Wu W.C., Jiang L., Friedmann P.D., Trivedi A. Association between process quality measures for heart failure and mortality among US veterans. Am Heart J 2014, 168:713-720.
16. Armstrong K., Berlin M., Schwartz J.S., Propert K., Ubel P.A. Barriers to influenza immunization in a low-income urban population. Am J Prev Med 2001, 20:21-25.
17. Zhou L., Su Q., Xu Z., et al. Seasonal influenza vaccination coverage rate of target groups in selected cities and provinces in China by season (2009/10 to 2011/12). PLoS ONE 2013, 8:e73724.
18. Chang Y.C., Huang N., Chen L.S., Hsu S.W., Chou Y.J. Factors affecting repeated influenza vaccination among older people in Taiwan. Vaccine 2013, 31:410-416.
19. World Health Organization. Health Topics. Influenza. 2015. Available at: Accessed October 19, 2015. http://www.who.int/topics/influenza/en/.
20. Straits-Troster K.A., Kahwati L.C., Kinsinger L.S., Orelien J., Burdick M.B., Yevich S.J. Racial/ethnic differences in influenza vaccination in the Veterans Affairs Healthcare System. Am J Prev Med 2006, 31:375-382.
21. Kopel E., Klempfner R., Goldenberg I. Influenza vaccine and survival in acute heart failure. Eur J Heart Fail 2014, 16:264-270.
22. Nichol K.L., Nordin J., Mullooly J., Lask R., Fillbrandt K., Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003, 348:1322-1332.
23. Liu I.F., Huang C.C., Chan W.L., et al. Effects of annual influenza vaccination on mortality and hospitalization in elderly patients with ischemic heart disease: a nationwide population-based study. Prev Med 2012, 54:431-433.
24. Vardeny O., Sweitzer N.K., Detry M.A., Moran J.M., Johnson M.R., Hayney M.S. Decreased immune responses to influenza vaccination in patients with heart failure. J Card Fail 2009, 15:368-373.
25. Vardeny O., Moran J.J., Sweitzer N.K., Johnson M.R., Hayney M.S. Decreased T-cell responses to influenza vaccination in patients with heart failure. Pharmacotherapy 2010, 30:10-16.
26. Van Ermen A., Hermanson M.P., Moran J.M., Sweitzer N.K., Johnson M.R., Vardeny O. Double dose vs. standard dose influenza vaccination in patients with heart failure: a pilot study. Eur J Heart Fail 2013, 15:560-564.